HLS Therapeutics (TSE:HLS) Stock Price Down 0.5% - Here's What Happened

Key Points

• HLS Therapeutics' stock price decreased by 0.5% to C$5.62, with trading volume falling 69% below its average.
• Raymond James Financial upgraded HLS Therapeutics from a "hold" to a "moderate buy" rating, raising the target price from C$5.00 to C$6.00.
• The company specializes in branded pharmaceutical products focused on central nervous system and cardiovascular treatments.

HLS Therapeutics Inc. (TSE:HLS - Get Free Report)'s share price fell 0.5% during trading on Tuesday . The company traded as low as C$5.59 and last traded at C$5.62. 4,166 shares changed hands during trading, a decline of 69% from the average session volume of 13,446 shares. The stock had previously closed at C$5.65.

Analyst Upgrades and Downgrades

Separately, Raymond James Financial upgraded HLS Therapeutics from a "hold" rating to a "moderate buy" rating and lifted their target price for the company from C$5.00 to C$6.00 in a research report on Thursday, August 21st. One investment analyst has rated the stock with a Hold rating, According to MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of C$5.00.

HLS Therapeutics Stock Down 0.5%

The firm's fifty day moving average price is C$5.37 and its 200-day moving average price is C$4.91. The company has a market capitalization of C$176.43 million, a price-to-earnings ratio of -11.71 and a beta of 0.49. The company has a debt-to-equity ratio of 86.50, a current ratio of 1.56 and a quick ratio of 1.01.

HLS Therapeutics Company Profile

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.